Skip to main content

Advertisement

SpringerLink
Log in

Trastuzumab in HER2-Positive Metastatic Gastric Cancer

Profile Report

  • Adis Profile Report
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Parkin D, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108

    Article  PubMed  Google Scholar 

  2. Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw 2010 Apr; 8 (4): 437–47

    PubMed  CAS  Google Scholar 

  3. Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008; 68 (3): 299–317

    Article  PubMed  CAS  Google Scholar 

  4. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003; 14Suppl. 2: ii41–4

    PubMed  Google Scholar 

  5. Wagner AD, Wedding U. Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging 2009; 26 (8): 627–46

    Article  PubMed  CAS  Google Scholar 

  6. Allum WH, Griffin SM, Watson A, et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2002 Jun; 50Suppl. 5: v1–23

    Article  PubMed  Google Scholar 

  7. Ajani J, Bekaii-Saab T, D’Amico TA, et al. Gastric cancer clinical practice guidelines. J Natl Compr Canc Netw 2006 Apr; 4 (4): 350–66

    PubMed  CAS  Google Scholar 

  8. Moehler M, Lyros O, Gockel I, et al. Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 2008 Jun 28; 14 (24): 3773–80

    Article  PubMed  Google Scholar 

  9. Lordick F, Peschel C, Siewert JR. Antibody-based targeted therapy for gastric cancer. Gastric Cancer 2005; 8 (4): 206–8

    Article  PubMed  Google Scholar 

  10. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005 Oct 20; 353 (16): 1652–4

    Article  PubMed  CAS  Google Scholar 

  11. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19 (9): 1523–9

    Article  PubMed  CAS  Google Scholar 

  12. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004 May; 4 (5): 361–70

    Article  PubMed  CAS  Google Scholar 

  13. Plosker GL, Keam SJ. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 2006; 66 (4): 449–75

    Article  PubMed  CAS  Google Scholar 

  14. Ruschoff J, Nagelmeier I, Baretton G, et al. HER2 testing in gastric cancer. what is different in comparison to breast cancer? [in German]. Pathologe 2010 May; 31 (3): 208–17

    Article  PubMed  CAS  Google Scholar 

  15. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008 Jun; 52 (7): 797–805

    Article  PubMed  CAS  Google Scholar 

  16. Meza-Junco J, Au H-J, Sawyer MB. Trastuzumab for gastric cancer. Expert Opin Biol Ther 2009; 9 (12): 1543–51

    Article  PubMed  CAS  Google Scholar 

  17. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62 (1): 209–43

    Article  PubMed  CAS  Google Scholar 

  18. Perry CM, Wiseman LR. Trastuzumab. Biodrugs 1999 Aug; 12 (2): 129–35

    Article  PubMed  CAS  Google Scholar 

  19. Garnock-Jones KP, Keating GM, Scott LJ. Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 2010; 70 (2): 215–39

    Article  PubMed  CAS  Google Scholar 

  20. European Medicines Agency. Herceptin: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf [Accessed 2010 Oct 18]

  21. Genetech, Inc. Herceptin® (trastuzumab): prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf [Accessed 2010 Oct 27]

  22. Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs 2010; 70 (17): 2259–67

    Article  PubMed  CAS  Google Scholar 

  23. Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract no. 4556]. J Clin Oncol 2009 May 20; 27: 15S. Plus poster presented at the 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–Jun 2; Orlando (FL)

    Article  Google Scholar 

  24. Chung H, Bang Y, Xu J, et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing [abstract no. 6511 plus poster]. 15th European Cancer Conference and the 34th Congress of the European Society of Medical Oncology; 2009 Sep 20–24; Berlin

  25. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376 (9742): 687–97

    Article  PubMed  CAS  Google Scholar 

  26. European Medicines Agency. Assessment report for Herceptin [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000278/WC500074921.pdf [Accessed 2010 Oct 19]

Download references

Acknowledgments and Disclosures

The original article[22] from which this profile report was derived was reviewed by C. Hudis,Department of Medicine, Memorial Sloan-Kettering Center, New York, NY, USA; B. Leyland-Jones, McGill University, Montreal, QC, Canada; A.D. Wagner, Multidisciplinary Oncology Center, University of Lausanne Hospitals, Lausanne, Switzerland.

The manufacturer of the agent under review was offered an opportunity to comment on the original article during the peer review process. Changes based on any comments received were made by the authors on the basis of scientific and editorial merit. The preparation of the original article and this profile report was not supported by external funding.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Jamie D. Croxtall & Kate McKeage

Authors
  1. Jamie D. Croxtall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jamie D. Croxtall.

Additional information

Adapted and reproduced from the original article published in Drugs 2010; 70 (17): 2259–2267

Rights and permissions

Reprints and permissions

About this article

Cite this article

Croxtall, J.D., McKeage, K. Trastuzumab in HER2-Positive Metastatic Gastric Cancer. BioDrugs 25, 257–259 (2011). https://doi.org/10.2165/11207110-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11207110-000000000-00000

Keywords

Search

Navigation